HepG2 Stable Cell Line Generation
HepG2 cells have been demonstrated to be Neomycin G418 resistant (400 µg/mL). Development of HepG2 stable cell line services are provided by Altogen Labs CRO. Development of stable cell lines in 28 days that over-express a protein of interest (or shRNA construct) are vital research tools, especially for the production of recombinant antibodies proteins, studying gene functions and screening therapeutics. Stable cell lines grow for extended periods of time and continue to express a transgene.
*NOTE: All IP rights to the HepG2 cell line belongs solely to the Wistar Institute.
Copyright picture from Altogen.com. Reproduced with permission from Altogen Biosystems.